What does DEFTA Partners invest in?
DEFTA Partners invests most often at Series A and Series B (82% of the rounds on record), in sectors such as Healthcare, Ict and Biotechnology.

United States · Investor
Last cheque observed Nov 2019. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.
QuietNew fund $63M, Jun 2019VC firm
Follow DEFTA Partners and see its new cheques in your feed.Start following
11 rounds on record
Mostly Series A and Series B: 82% of its rounds
3 exits from the portfolio
Since the 1980s, DEFTA Partners has identified, nurtured, and funded companies with innovative technologies.From their own website
Every round we can evidence, newest first11 appearances
4 rounds
1 round
1 round
1 round
1 round
1 round
1 round
1 round
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
Named by the firm itself, on a filing, its Form ADV or its company registration1 named
We also hold 5 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
From their own portfolio page (on their website)
QoloAlio_Logo_editedBacchus_Logo_editedCMED_Logo_editedCambrian_Biopharma_Logo2_editedPhotoQ3RtfStartribuneanamne_main_edited
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Companies it backed that were later bought or listed3 in all
An exit counts when it came after the firm's first round in the company. From historical deal records.
The investors most often in the same rounds as DEFTA Partners. A count of rooms they were both in, not a relationship either has claimed.
The latest companies DEFTA Partners put money into.
DEFTA Partners invests most often at Series A and Series B (82% of the rounds on record), in sectors such as Healthcare, Ict and Biotechnology.
11 investments on record, 0 of them in the last 12 months. The most recent was in Nov 2019.
Its most recent investments on record: Actuate (Series B, Nov 2019), BioEclipse Therapeutics (Series A, Jun 2019) and Actuate Therapeutics (Series B, May 2019).
The median round it joins is $9.6M. It says it writes cheques of $500K to $3.0M.
Rarely, if at all: none of its 11 investments on record names it as the lead.
Most of the companies it backs are in the United States (100%).
No investments in the last 12 months; the latest was in Nov 2019.
Most often Edmond de Rothschild Venture Capital (3 rounds together), Walden Venture Capital (3 rounds together) and Bios Partners (2 rounds together).
Find the investors who back rounds like yours, and keep every conversation on one fundraising board.
Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it